“Muna Therapeutics, a biotech company based in Denmark, Belgium and the US, discovers and develops medicines that protect the brain and slow or stop the progression of neurodegenerative diseases, which affect cognition, behavior and quality of life for millions of patients and their loved ones around the globe. Muna’s most advanced potential medicine for Alzheimer’s disease was enabled by more than 25 years of discovery-led research conducted by scientists and clinicians across the EU and around the globe, and will be in human safety testing in 2025,” said Rita Balice-Gordon, CEO Muna Therapeutics.

Today we feature @ritabg.bsky.social, CEO #MunaTherapeutics (Denmark, Belgium & US), a company that develops #therapies that slow or stop devastating neurodegenerative diseases incl. #Alzheimer’s & #Parkinson’s

#FundamentalResearch for #EUcompetitiveness

EU-LIFE #innovation ➡️ eu-life.eu/innovation